Literature DB >> 30814731

Structure of the IFNγ receptor complex guides design of biased agonists.

Nichole K Escalante1,2, Kevin M Jude3,4, Junel Sotolongo Bellon5, Juan L Mendoza3,4,6, Leon Su3,4, Tim M Horton3,4, Naotaka Tsutsumi3,4, Steven J Berardinelli7, Robert S Haltiwanger7, Jacob Piehler5, Edgar G Engleman1,2, K Christopher Garcia8,9.   

Abstract

The cytokine interferon-γ (IFNγ) is a central coordinator of innate and adaptive immunity, but its highly pleiotropic actions have diminished its prospects for use as an immunotherapeutic agent. Here, we took a structure-based approach to decoupling IFNγ pleiotropy. We engineered an affinity-enhanced variant of the ligand-binding chain of the IFNγ receptor IFNγR1, which enabled us to determine the crystal structure of the complete hexameric (2:2:2) IFNγ-IFNγR1-IFNγR2 signalling complex at 3.25 Å resolution. The structure reveals the mechanism underlying deficits in IFNγ responsiveness in mycobacterial disease syndrome resulting from a T168N mutation in IFNγR2, which impairs assembly of the full signalling complex. The topology of the hexameric complex offers a blueprint for engineering IFNγ variants to tune IFNγ receptor signalling output. Unexpectedly, we found that several partial IFNγ agonists exhibited biased gene-expression profiles. These biased agonists retained the ability to induce upregulation of major histocompatibility complex class I antigen expression, but exhibited impaired induction of programmed death-ligand 1 expression in a wide range of human cancer cell lines, offering a route to decoupling immunostimulatory and immunosuppressive functions of IFNγ for therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30814731      PMCID: PMC6561087          DOI: 10.1038/s41586-019-0988-7

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  3 in total

1.  Comparative effects of various classes of mouse interferons on macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; P A LeBlanc; D M Murasko
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

2.  A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice.

Authors:  C Nakajima; Y Uekusa; M Iwasaki; N Yamaguchi; T Mukai; P Gao; M Tomura; S Ono; T Tsujimura; H Fujiwara; T Hamaoka
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Importance of the loop connecting A and B helices of human interferon-gamma in recognition by interferon-gamma receptor.

Authors:  D Lundell; C A Lunn; M M Senior; P J Zavodny; S K Narula
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

  3 in total
  32 in total

Review 1.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

2.  Molecular engineering strategies for visualizing low-affinity protein complexes.

Authors:  Qianqian Ming; David Gonzalez-Perez; Vincent C Luca
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-11

3.  Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response.

Authors:  Han-Po Shih; Jing-Ya Ding; Junel Sotolongo Bellón; Yu-Fang Lo; Pei-Han Chung; He-Ting Ting; Jhan-Jie Peng; Tsai-Yi Wu; Chia-Hao Lin; Chia-Chi Lo; You-Ning Lin; Chun-Fu Yeh; Jiun-Bo Chen; Ting-Shu Wu; Yuag-Meng Liu; Chen-Yen Kuo; Shang-Yu Wang; Kun-Hua Tu; Chau Yee Ng; Wei-Te Lei; Yu-Huan Tsai; Jou-Han Chen; Ya-Ting Chuang; Jing-Yi Huang; Félix A Rey; Hung-Kai Chen; Tse-Wen Chang; Jacob Piehler; Chih-Yu Chi; Cheng-Lung Ku
Journal:  J Exp Med       Date:  2022-07-14       Impact factor: 17.579

Review 4.  Emerging principles of cytokine pharmacology and therapeutics.

Authors:  Robert A Saxton; Caleb R Glassman; K Christopher Garcia
Journal:  Nat Rev Drug Discov       Date:  2022-09-21       Impact factor: 112.288

5.  Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.

Authors:  Preeti Sharma; Venkata V V R Marada; Qi Cai; Monika Kizerwetter; Yanran He; Steven P Wolf; Karin Schreiber; Henrik Clausen; Hans Schreiber; David M Kranz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-15       Impact factor: 11.205

6.  Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist.

Authors:  Caleb R Glassman; Leon Su; Sonia S Majri-Morrison; Hauke Winkelmann; Fei Mo; Peng Li; Magdiel Pérez-Cruz; Peggy P Ho; Ievgen Koliesnik; Nadine Nagy; Tereza Hnizdilova; Lora K Picton; Marek Kovar; Paul Bollyky; Lawrence Steinman; Everett Meyer; Jacob Piehler; Warren J Leonard; K Christopher Garcia
Journal:  Elife       Date:  2021-05-18       Impact factor: 8.140

Review 7.  Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes.

Authors:  Monikaben Padariya; Alicja Sznarkowska; Sachin Kote; Maria Gómez-Herranz; Sara Mikac; Magdalena Pilch; Javier Alfaro; Robin Fahraeus; Ted Hupp; Umesh Kalathiya
Journal:  Biomolecules       Date:  2021-04-22

8.  Optimal ligand discrimination by asymmetric dimerization and turnover of interferon receptors.

Authors:  Patrick Binder; Nikolas D Schnellbächer; Thomas Höfer; Nils B Becker; Ulrich S Schwarz
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

Review 9.  Interferon target-gene expression and epigenomic signatures in health and disease.

Authors:  Franck J Barrat; Mary K Crow; Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2019-11-19       Impact factor: 25.606

Review 10.  Interferon-γ: teammate or opponent in the tumour microenvironment?

Authors:  Angela M Gocher; Creg J Workman; Dario A A Vignali
Journal:  Nat Rev Immunol       Date:  2021-06-21       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.